Spevigo prevents generalized pustular psoriasis flares up to 48 weeks

Spevigo met its primary and key secondary endpoints in a phase 2b trial evaluating the drug for the treatment of adolescents and adults with generalized pustular psoriasis, Boehringer Ingelheim announced in a press release.

Spevigo (spesolimab), an investigational drug that targets the interleukin-36 pathway, was approved by the FDA for the treatment of generalized pustular psoriasis (GPP) in September 2022. The approval was based on positive results from the EFFISAYIL 1 trial.

The new top-line results from the EFFISAYIL 2 trial — a multicenter, randomized, double-blind, placebo-controlled phase 2b study — has shown that the use of subcutaneous spesolimab can prevent GPP flares and sustain control of symptoms in adolescents and adults.

According to the release, EFFISAYIL 2 met its primary and key secondary endpoints, which demonstrated that spesolimab can prevent GPP flares up to 48 weeks.

“Painful GPP flares can occur suddenly, escalate quickly, and may require urgent hospital care leaving people anxious and uncertain about what the future might hold,” Carinne Brouillon, PharmD, member of the board of managing directors and head of human pharma at Boehringer Ingelheim, said in the release. “The EFFISAYIL 2 results reinforce the potential of spesolimab to prevent GPP flares, giving patients the power to plan their lives, regardless of their disease.”

The company plans to present the EFFISAYIL 2 results later this year.